Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB195 in Urea Cycle Disorder
NCT03933410Phase 2Terminated
- Sponsor
- Kaleido Biosciences
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of onterodrimer in urea cycle disorder (UCD), sponsored by Kaleido Biosciences. Primary endpoint: Proportion of subjects who achieve a ≥15% reduction from baseline in fasting plasma ammonia at Day 55. Started Sep 2019; status: terminated.
02
Drugs
onterodrimer
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on NCT03933410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933410.